Generation Bio Co. (NASDAQ:GBIO) Receives Average Rating of “Hold” from Analysts

Generation Bio Co. (NASDAQ:GBIO) has been given a consensus rating of “Hold” by the six research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $8.8750.

Several research analysts have weighed in on the company. Wedbush set a $5.50 price target on Generation Bio and gave the stock an “outperform” rating in a research report on Tuesday, December 16th. Jefferies Financial Group cut shares of Generation Bio from a “buy” rating to a “hold” rating and decreased their target price for the company from $11.00 to $5.00 in a research note on Tuesday, December 16th. Citigroup reaffirmed a “market perform” rating on shares of Generation Bio in a research report on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Generation Bio in a research note on Friday, November 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research note on Wednesday, October 8th.

Institutional Trading of Generation Bio

Institutional investors and hedge funds have recently bought and sold shares of the business. Shay Capital LLC acquired a new stake in shares of Generation Bio in the third quarter valued at approximately $64,000. ADAR1 Capital Management LLC acquired a new position in shares of Generation Bio during the 3rd quarter worth approximately $136,000. AQR Capital Management LLC bought a new stake in Generation Bio in the 1st quarter valued at $36,000. Cantor Fitzgerald L. P. acquired a new stake in Generation Bio during the 3rd quarter valued at $606,000. Finally, Marshall Wace LLP acquired a new stake in Generation Bio during the 2nd quarter valued at $37,000. Institutional investors own 95.22% of the company’s stock.

Generation Bio Price Performance

Shares of NASDAQ:GBIO opened at $5.48 on Friday. The company’s 50-day moving average price is $5.38 and its two-hundred day moving average price is $5.34. Generation Bio has a one year low of $3.00 and a one year high of $10.40. The stock has a market capitalization of $36.94 million, a PE ratio of -0.59 and a beta of 2.05.

Generation Bio (NASDAQ:GBIO) last released its earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.18) by $2.36. Generation Bio had a negative return on equity of 94.82% and a negative net margin of 410.13%.The business had revenue of $1.59 million for the quarter, compared to the consensus estimate of $0.66 million. On average, analysts anticipate that Generation Bio will post -1.75 earnings per share for the current fiscal year.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.